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Abstract: Introduction: Hypovitaminosis D is highly prevalent and constitutes a public health problem 
worldwide. It can affect more than 90% of individuals, depending on the population studied. Objective: To make 
a broad analysis of the world literature to compose the State of the Art on serum vitamin D levels and its adequate 
supplementation, to prevent and mitigate various diseases, based on randomized clinical studies, analysis, and 
latest international conferences and consensus. Methods: The present study followed a literary review of 
randomized clinical studies, meta-analysis, and the latest international consensus. Cochrane instrument was 
adopted to assess the quality of the included studies between 2015 and 2020. Major considerations and 
conclusion: Laboratory evaluation should be performed by measuring 25(OH)D, and the main groups of 
individuals at risk for vitamin D deficiency are the elderly, patients with osteoporosis, history of falls and fractures, 
obese, pregnant women, and infants. For patients with osteoporosis and increased risk of fractures, recommended 
that concentrations of 25(OH)D remain above 30 ng/mL for full benefits on the prevention of secondary 
hyperparathyroidism, decreased risk of falls. Special considerations must have taken to pregnant women and 
infants, in patients with chronic renal failure, obese patients, and those undergoing bariatric surgery. Several 
clinical studies and current meta-analysis have shown significant results with vitamin D supplementation in 
cardiovascular complications, diabetes, cancer, autoimmune diseases, cognitive function, among others, with doses 
above 30 ng/mL, reaching up to 70 ng/mL, and maintaining serum dosage at 50 ng/mL. 
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Introduction 
Hypovitaminosis D is highly prevalent and 
constitutes a public health problem worldwide. Studies 
show a high prevalence of this disease in several 
geographic regions, including Brazil. It can affect more 
than 90% of individuals, depending on the population 
studied [1]. Vitamin D is essential in functions related 
to bone metabolism, but it also seems to be related to 
the pathophysiology of several diseases. In children, 
vitamin D deficiency leads to growth retardation and 
rickets [2]. In adults, hypovitaminosis D leads to 
osteomalacia, secondary hyperparathyroidism, and, 
consequently, increased bone resorption, favoring 
bone loss, and the development of osteopenia and 
osteoporosis. Muscle weakness can also occur, which 
contributes to further increase the risk of falls and 
bone fractures in patients with low bone mass [3]. 
Deficiency of vitamin D (serum 25-
hydroxyvitamin D (25 (OH) D) <50 nmol/L or 20 
ng/mL) is common than is thought in the majority of 
the world population. It occurs in <20% of the 
population in northern Europe, in 30-60% in western, 
southern, and eastern Europe and up to 80% in Middle 
Eastern countries [4]. Severe deficiency (serum 25 
(OH) D <30 nmol/L or 12 ng/mL) is found in > 10% of 
Europeans. The European Society of Calcified Tissues 
(ECTS) recommends that the measurement of serum 
25 (OH) D be standardized by a Vitamin D 
Standardization Program. Risk groups include young 
children, adolescents, pregnant women, the elderly 
(mainly institutionalized), and non-Western immigrants 
[2]. 
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The consequences of vitamin D deficiency 
include mineralization defects and lower bone mineral 
density, causing fractures. The extra-skeletal 
consequences can be muscle weakness, falls, and 
acute respiratory infection, and are the subject of large 
ongoing clinical trials. ECTS advise improving vitamin D 
status by fortifying food and using vitamin D 
supplements in risk groups [2]. 
Fortification of foods by adding vitamin D to 
dairy products, bread, and cereals can improve the 
vitamin D status of the entire population, but quality 
assurance needs to be monitored to prevent poisoning. 
Specific risk groups such as babies and children up to 
3 years old, pregnant women, the elderly, and non-
Western immigrants should routinely receive vitamin D 
supplements. Future research should include genetic 
studies to better define individual vulnerability to 
vitamin D deficiency and Mendelian randomization 
studies for the effect of vitamin D deficiency on long-
term non-skeletal outcomes, such as cancer [3].  
The correct diagnosis of this condition and the 
identification of factors that improve or worsen may 
contribute to the development of more effective 
strategies for the treatment of populations at risk, such 
as the elderly and postmenopausal women [5]. Thus, 
the efforts of the Bone Metabolism Department of the 
Brazilian Society of Endocrinology and Metabology 
(SBEM) are increasing in the development of 
recommendations based on the evidence available in 
the scientific literature for the diagnosis and treatment 
of this condition [6]. 
In this context, parathyroid cells express the 
enzyme 1-alpha-hydroxylase and can synthesize the 
active form, 1.25(OH)2D intracellularly, from the 
serum pool of 25(OH)D [7]. In situations of 
hypovitaminosis D, the lower intracellular synthesis 
leads to secondary hyperparathyroidism that is 
associated with increased bone resorption. There is an 
inverse correlation between PTH and 25 (OH) D, 
described in children and the elderly. Several cutoff 
values of 25(OH)D for normalization of PTH have been 
published, and most are concentrated between 28 and 
40 ng/mL (70 to 100 nmol/L) [8]. 
The absorption of calcium by the intestine is 
dependent on the action of active vitamin D in the 
duodenum, through a saturable transcellular process, 
whose stimulus leads to the synthesis of proteins such 
as calbindin-D9k (CaBP-9k) and the epithelial apical 
channel TRPV6 [8]. However, there is evidence that 
the unsaturated transport that occurs with part of the 
absorption of calcium in the human ileum also 
influences vitamin D [9-12]. 
Therefore, the present study aimed to make a 
broad analysis of the world literature to compose the 
State of the Art on serum vitamin D levels and its 
adequate supplementation, to prevent and mitigate 
various diseases, based on randomized clinical studies, 





The present study followed a literary review of 
randomized clinical studies, meta-analysis, and the 
latest international consensus, following the rules of 
the PRISMA 2009. Available in: http://www.prisma-
statement.org/      
Table 1 shows the main variables of the 
present study that have addressed according to the 
classification of the acronym PICOS (P = Patients; I = 
Intervention; C = Control (Control); O = Outcomes; S 
= Study Design (Type of studies). 
 
Study eligibility criteria 
Only randomized clinical studies, systematic 
reviews, meta-analysis, and the latest international 
conferences and consensus included. 
 
Selection of studies and risk of bias in each 
study 
The Cochrane instrument was adopted to 
assess the quality of the included studies [13]. 
 
Data sources and research strategy 
The search strategies for this systematic 
review have based on the keywords (MeSH Terms) 
“Vitamin D; (25(OH)D); Hypovitaminosis; Immunity; 
Inflammatory Process; Disease trigger; Acute 
respiratory syndrome; COVID-19; SARS-CoV-2 ”, with 
publications from 2015 to 2020, to analyze the most 
recent scientific publications. The SCOPUS (Elsevier 
and non-Elsevier database), COCHRANE Library, 
PubMed (MEDLINE biomedical literature, life science 
magazines, and online books) and SCIENCE DIRECT 
(Elsevier database) databases were used, including the 
National Institutes of Health RePORTER Grant 
database and clinical trial records. Also, a combination 
of keywords with the Booleans OR, AND, and the 
operator NOT have used to target scientific articles of 
interest.  
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The title and abstracts were examined under 
all conditions. The research structure used in the 
databases was shown in Table 2. 
 
Results and Discussion 
Main current outcomes 
The 2nd International Conference on Vitamin D 
Controversies was held in Monteriggioni (Siena), Italy, 
from 11 to 11 September 14, 2018 [2]. The purpose of 
this meeting was to address controversies and timely 
topics in vitamin D research, to review the available 
data related to these topics and controversies, to 
promote discussions to help resolve remaining 



























to clarify areas of uncertainty. Several 
questions from the first conference (2017) have 
revised, such as assays used to determine the serum 
concentration of 25-hydroxyvitamin D (25(OH)D), 
which remains a critical and controversial issue to 
define the status of vitamin D. State definitions 
nutritional status (ie sufficiency, insufficiency, and 
deficiency) have also reviewed. New areas have been 
revised, including vitamin D threshold values and how 
they should be defined in the context of specific 
diseases, sources of vitamin D, and risk factors 
associated with vitamin D deficiency. Also discussed 
were non-skeletal aspects related to vitamin D, 
including to reproductive system, neurology, chronic 























Resolution or reduction of symptoms and complications. 
 







Randomized clinical studies, systematic reviews, meta-analysis 























Case reports OR Active vitamin D analogues 
Table 1. Table of PICOS (Patients; Intervention; Control; Outcomes; Study Design). 
 
Table 2. An example of the search structure in PubMed, the same search strategy was used in 
the other databases. 
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therapeutic role of vitamin D and the findings of recent 





1. Existing data is insufficient to define "low" or "high" thresholds for vitamin D status with any 
degree of certainty due to the lack of standardized 25 (OH) D measurements in vitamin D 
research. 
 
2. The current approach to defining vitamin D status using a concentration of 25 (OH) D. 
 
3. Due to the variability of the test, the circulation of “25 (OH) D”, measured by the multiplicity 
of existing tests, cannot be simply blindly grouped in meta-analysis. 
 
4. For research and publication of data, 25 (OH) D assays should demonstrate standardization 
or alignment with reference methodology. 
 
5. Laboratories must participate in a proficiency testing program based on the accuracy of 25 
(OH) D, p. DEQAS, or College of American Pathologists. 
 
6. Some documentation that the 25 (OH) D test methodology works correctly in the study 
environment (for example, pregnancy, hemodialysis). Given the deficiencies in the tests, 
manufacturers should develop tests with a comparable capacity to accurately measure 25 
(OH) D2 and 25 (OH) D3 in various clinical circumstances. 
 
7. It seems reasonable to recommend cholecalciferol instead of ergocalciferol. 
 
8. The risk of developing rickets/osteomalacia increases at a concentration of 25 (OH) D <30 
nmol/L. This threshold may vary depending on other conditions, such as calcium and 
phosphate nutrition, parathyroid hormone (PTH) levels, and season. 
 
9. The concentration of 25 (OH) D varies between normal individuals between approximately 
50-125 nmol/L. With admitted uncertainty, an upper 25 (OH) D threshold of 125 nmol/L is 
advisable. 
 
10. The most recent food content analysis of vitamin D confirms low vitamin D content in non-
fortified food supplies. 
 
11. There appear to be differences in bioavailability and availability, perhaps biological effects 
between 25 (OH) D3 and 25 (OH) D2 under certain circumstances. 
 
12. Vitamin D or 25 (OH) D3 can be added to the food supply by feeding animals enriched food. 
 
13. The latest data on exposure to very high natural levels exposure to sunlight has led to 
uncertainty about how much vitamin D3 can be produced after exposure to the sun. 
 
14. Individuals with dark skin can produce vitamin D3 to a greater extent than previously 
thought. 
 
15. The use of sunscreen does not significantly affect the production of vitamin D3 in the skin. 
 
16. Glucocorticoids are associated with vitamin D deficiency and/or resistance. 
 
17. Pathophysiology appears to be multifactorial. 
 
18. Vitamin D supplementation improves skeletal health in glucocorticoid-induced osteoporosis 
when combined with calcium. 
 
19. The precise effects of active vitamin D compounds in the treatment of some very common 
Table 3. Declarations of the Second International Conference [2]. 
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complications of chronic kidney disease are far from fully established. 
 
20. Pending more solid data, it can be assumed that oral vitamin D, such as cholecalciferol, can 
provide benefits in various clinical settings related to chronic kidney disease. 
 
21. Vitamin D is essential to prevent rickets and osteomalacia. 
 
22. Vitamin D metabolites, except the active metabolite. 
 
23. May play a role in fracture repair. 
 
24. Vitamin D supplementation with adequate calcium intake. 
 
25. It can decrease the incidence of fractures in the elderly. 
 







1. The relationship between vitamin D status and cancer is based on plausible in vitro data, data 
from animals, and clinicians. 
 
2. Randomized clinical studies indicate that vitamin D supplementation did not significantly 
reduce the risk of cancer, but significantly improved cancer survival. However, deficiencies in 
the test designs provide a cautionary note. 
 
3. Appropriate selection of subjects (perhaps starting with a high-risk population) and other 
variables should be considered as components of the ideal project. 
 
4. Studies to determine the effect of vitamin D on cancer risk should be carried out for more 
than 3-5 years, given the time course of oncogenesis. 
 
5. Vitamin D may be involved in the pathogenesis of Chron's disease in line with its potential 
role in the immune response, as it occurs in other autoimmune diseases. 
 
6. Due to the heterogeneity in the study design, different serum concentrations, baseline levels 
of vitamin D and different doses of vitamin D administered in studies, the harmonization of 
these variables is a prerequisite for the interpretation of the potential role of vitamin D in 
autoimmune diseases. 
 
7. It is known that obesity and diabetes are associated with vitamin D deficiency, but the 
mechanisms involved have not yet been elucidated. 
 
8. Vitamin D supplementation has not been shown to improve outcome measures for diabetes 
and obesity. 
 
9. Bariatric surgery has several important results related to vitamin D metabolism, including 
reduced absorption. 
 
10. Severe vitamin D deficiency is common in patients after bariatric surgery and correction 
require much more doses compared to obese people, which requires higher doses than non-
obese individuals. 
 
11. Calcium malabsorption may persist after correction of vitamin D deficiency due to reduced 
intestinal activity that activates calcium absorption. 
 
12. These patients have an increased fracture rate compared to obese people of the same age. 
Table 4. Vitamin D as a risk factor for non-skeletal health [2]. 
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13. The adequacy of vitamin D for mothers and babies is important. 
 
14. The implication of vitamin D deficiency during pregnancy is not fully understood. Results from 
meta-analysis suggest that improving maternal vitamin D status may decrease the risk of 
pregnancy outcome and may have long-term effects as well as beneficial effects on the child, 
such as asthma. 
 
15. Chronic vitamin D deficiency in animals can predispose to the development of chronic 
degenerative neurological diseases. 
 
16. Chronic degenerative neurological diseases in humans have been linked to vitamin D 
deficiency, but a potential causative role remains elusive. 
 
17. Vitamin D deficiency is associated with muscle dysfunction and decreases in the elderly. 
 
18. Vitamin D supplementation may reduce or increase the risk of falls in individuals moderately 
deficient in vitamin D. 
 
19. The ability to "see" or "not to see" an effect on falls and perhaps other results of vitamin D 




















 Secondary hyperparathyroidism; 
 Increase in bone resorption; 







 Obese people have lower vitamin D than non-obese 
people; 
 Bar Bariatric surgery as an aggravating factor; 







 The low weight of the newborn; 
 Low bone mass; 
 Cardiovascular risk markers in children; 
 Gestational diabetes, pre-eclampsia; 










 Regulation of genes involving the production of 
renin; 
 the proliferation of cardiac and vascular muscle 
cells; 
 Negativa negative regulation of C-reactive protein 
and other pro-inflammatory factors; 
 40% increase in the risk of death from coronary 
artery disease (CAD); 
 Grave Severe vitamin D deficiency in patients with 
stabilized CVD is related to 50% more death from 
stroke and three to five times more sudden death; 








 Reduces insulin resistance and increases its secretion, 





Table 5. Important recommendations from 25 (OH) D [2,3]. 
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Diabetes  Epidemiological studies show that children with vitamin 
D deficiency have a 2.4-fold increased risk of 
developing DM1. 
 In the EURODIAB study, there was a 33% reduction in 











 Correlation between levels of heatstroke and mortality 
from some types of cancer, as well as skin color seems 
to be related to the increased prevalence of colorectal, 
breast, and prostate cancer; 
 A decrease in 1-alpha hydroxylase (CYP27B1) and 
vitamin D receptor (VDR) is observed as cancer 
progresses; 
 In vitro and in vivo studies show the direct or indirect 
effect of 1.25 (OH) 2D3 and its analogs on 
proliferation, differentiation, apoptosis, angiogenesis, 
invasion, and inflammation of malignant cells; 
 Microarray studies show that 1.25 (OH) 2D3 
influences the transcription of a large number of 











 1.25 (OH) 2D3 inhibits T cell proliferation, suppresses 
immunoglobulin synthesis and proliferation, prevents 
the formation of IFN-γ (interferon-γ) and IL-2 
(interleukin-2); 
 Increases the activity of suppressor T cells (TH2). 
 Interacts with factors inherited from MHC class II. 
 A high intake of vitamin D presents a 42% lower risk 













 Antimicrobial action, including Mycobacterium 
tuberculosis, by stimulating the production of 
cathelicidin (a protein that acts in the destruction of 
pathological agents); 
 High doses of vitamin D, 600,000 IU, in patients with 
tuberculosis, demonstrated greater weight gain and 
less residual disease in those who received the vitamin 
in comparison to controls. 
 A survey of postmenopausal women, who ingested 
2,000 IU of vitamin D per day, showed a 90% 
reduction in upper respiratory tract infections when 









 The active form of vitamin D is a potent inhibitor of 
keratinocyte proliferation and can be used safely in 
non-malignant hyperproliferative diseases of the 
skin, such as psoriasis; 
 Data from controlled, randomized studies show that 
the active form is an effective and well-tolerated 











 In children with asthma, the level of 25 (OH) D 
appears to correlate positively with disease control 
and lung function; 
 1,200 IU per day of vitamin D in children was 
associated with an 83% reduction in the risk of 
exacerbating the disease. It is assumed that the 
immunomodulatory effects of vitamin D and the 
effects on lung function may be useful for the 




  Reduced mobility, worsened muscle function, and  
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function in the 
elderly 
thus an increased risk of falls. 
 Vitamin D receptors have high concentrations in 
several areas of the central nervous system. 
Epidemiological studies have shown that low 
vitamin D intake is associated with cognitive 
decline, an increased risk of Alzheimer's disease and 
depression; 
 Formation and β-amyloid aggregation 
 Deregulation in the gabaergic system 





Table 5 below presents the main illnesses 
related to vitamin D deficiency or insufficiency, as well 
as the possible recommended doses according to the 
studies addressed at the Second International 
Conference and the current vitamin D status in 
European and Middle Eastern countries and strategies  
to prevent vitamin D deficiency (European Calcified 
Tissue Society position statement) [2,3]. 
 
Main Clinical Studies, Systematic Reviews 
and Meta-analysis - Last 3 Years 
  One study investigated whether the genetic 
variation associated with the concentration of vitamin 
D affected changes in bone mineral density (BMD) in 
response to an intervention in the diet for weight loss.  
In the two years of preventing excess weight 
using new dietary strategies, BMD has measured for 
424 participants who have randomly assigned to 1 of 4 
diets varying in macronutrient intake. A genetic risk 
score (GRS) has calculated based on three genetic 
variants, namely 7-dehydrocholesterol reductase 
(DHCR7) rs12785878, cytochrome P450 2R1 (CYP2R1) 
rs10741657 and group-specific component (GC) 
globulin rs2282679, listed in circulating levels of 
vitamin D. A significant GRS interaction has found 
between dietary fat intake and vitamin D at two years 
in full-body BMD. In the high-fat diet group, 
participants with the highest GRS showed significantly 
less reduction in full-body BMD with those with the 
lowest ERG, while genetic associations were not 
significant in the low-fat diet group. There was also a 
significant interaction between dietary fat intake and 
GRS in the 6-month change in femoral neck BMD [14]. 
Another study investigated the effect of 
normalizing vitamin D status and/or reducing levels of 
parathyroid hormone (PTH) on the activity of 





In a double-blind winter study, we randomized 
81 healthy postmenopausal women with secondary 
hyperparathyroidism (PTH> 6.9 pmol/L) and 25-
hydroxy-vitamin D (25 (OH) D) levels <50 nmol/L to 
12 weeks of treatment with vitamin D3 70 µg/day 
(2800 IU/day) or identical placebo. Compared to 
placebo, treatment with vitamin D3 significantly 
increased plasma levels of 25 (OH) D and 1.25 (OH) 
2D by 230% (95% CI: 189-272%) and 58% (190-
271%), respectively. Treatment with vitamin D3 
reduced PTH by 17% (11-23%) but did not reduce 
plasma changes, glycated hemoglobin, lipids and 
lipoproteins, blood pressure, vascular stiffness, heart 
rate, and cardiac conductivity. Compared to placebo, 
treatment with vitamin D3 increased plasma levels of 
high-density lipoproteins (HDL) by 4.6% (0.12-9.12%) 
but did not affect other measured indices [15]. 
A large number of observational studies have 
reported harmful effects of low levels of 25-
hydroxyvitamin D (25OHD) on non-skeletal results. A 
systematic review of the characteristics of the 
randomized controlled trials (RCTs) included in the 
meta-analysis on the non-skeletal effects of vitamin D 
supplementation carried out. Fifty-four systematic 
reviews were identified, including data from 210 RCTs. 
Beneficial effects of vitamin D supplementation have 
reported in 1 of 4 meta-analysis on depression, 2 of 9 
meta-analyzes on blood pressure, 3 of 7 meta-analysis 
on respiratory tract infections, and 8 of 12 meta-
analysis on mortality. Most RCTs performed primarily 
to determine skeletal outcomes, while non-skeletal 
effects were assessed as secondary outcomes. Only 
one-third of the randomized clinical trials had a low 
level of 25OHD as an inclusion criterion, and an initial 
mean level of 25OHD below 50 nmol/L was present in 
only less than half of the analyzes [16]. 
  Also, in a cross-sectional study, 104 healthy 
postmenopausal women with low levels of 25 (OH) D 
(<50 nmol/L), who had secondary 
hyperparathyroidism (SHPT) with high levels of PTH (> 
6.9 pmol) were investigated/L, n = 52) or normal PTH 
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levels (n = 52). The mean PTH value in women with 
SHPT was 8.5 (interquartile range 7.5-9.7) pmol / L 
5.3 (4.4-6.3) pmol/L in women with normal PTH (p < 
0.001). Plasma phosphate was significantly lower in 
women with SHPT than in women with normal PTH 
(1.01 ± 0.14 vs. 1.09 ± 0.13 mmol/L; p <0.01). In the 
total cohort, the mean level of 25 (OH) D was 38 (31-
45) nmol/L, with no differences between groups. SHPT 
was associated with impaired muscle strength, 
assessed by maximum muscle strength and maximum 
production of strength in knee flexion, with the knee 
fixed at 60 ° and 90 ° (p<0.05). Postural stability has 
impaired during the semi-tandem position (p=0.001). 
However, the two groups did not differ in terms of 
self-reported physical activity, symptoms related to 
muscles, quality of life, or lean muscle mass, assessed 
by dual-energy X-ray absorptiometry [17]. 
Besides, a placebo-controlled randomized 
clinical trial with 162 patients evaluated the effect of 
high doses of vitamin D on insulin sensitivity and risk 
of progression to diabetes. Of the total number of 
patients, only 83 completed the 6-month follow-up. 
After that time, serum 25-hydroxyvitamin D levels 
were significantly higher in the intervention group (36 
ng/mL vs. 16 ng/mL). There was no significant 
difference between fasting plasma glucose (FPG) or a 
2-hour glucose tolerance test (GTT). The score of the 
homeostatic insulin resistance model (HOMA-IR) was 
significantly lower in the vitamin D group (2.6 vs. 3.1). 
The rate of progression to diabetes was significantly 
lower in the intervention group (28% vs. 3%) [18]. 
Moreover, another randomized, placebo-
controlled study with 50 participants investigated 
vitamin D supplementation in executive functioning 
and mental health in a group of Norwegian teenagers 
during the winter who underwent blood collection and 
cognitive testing from the Tower of Hanoi (ToH) and 
London Tower. Participants with a low level of vitamin 
D had worse scores on the Tower of London tests and 
the more difficult subtasks on the Tower of Hanoi 
tests, as well as behavior problems and attention 
deficit. Before vitamin D supplementation, the general 
mean status of 25-hydroxyvitamin D was 42 nmol/L, 
and after supplementation, the average was 62 
nmol/L). Also, the group that received vitamin D 
supplementation improved their performance in the 
most demanding subtasks of ToH [19]. 
Another randomized, placebo-controlled clinical 
study was conducted on 100 overweight breeding 
women who were allocated to the treatment group, 
with 50 participants receiving 50,000 IU of vitamin D3 
per week. The observed follow-up was 2 months. 
There was a significant decrease in homocysteine 
levels, as well as an increase in the levels of 25 (OH) 
D, calcium, and phosphorus after the first and second 
months of intervention with vitamin D3 in the 
treatment group. However, there were no changes in 
the placebo group [20]. 
To increase and confirm the scientific 
evidence, a meta-analysis study of randomized 
controlled trials included 52 studies with a total of 
75,454 participants and performed analyzes on the 
vitamin D dose (≥ 2,000 and <2,000 IU/day), type of 
vitamin D (vitamin D2 and vitamin D3), treatment time 
(daily and intermittent), 25 basal hydroxyvitamin D 
dosage (≥50 and <50 nmol / L), and mean age (≥70 
and <70 years). The results showed that vitamin D 
supplementation was not associated with all causes of 
mortality, and significantly reduced the risk of life from 
cancer by 16%. Also, all causes of mortality were 
statistically lower in studies with vitamin D3 
supplementation than in studies with vitamin D2 
supplementation [21]. 
In this scenario, however, meta-analysis 
studies of randomized clinical studies have shown that 
lipid parameters, markers of inflammation, blood 
pressure, and arterial stiffness are not affected by 
vitamin D supplementation. Furthermore, it has not yet 
been shown that vitamin supplementation D in high 
doses or bolus reduces cardiovascular risks and 
consequently mortality, even in subgroups with 
concentrations of 25 (OH) D <50 nmol/L. Therefore, 
doses of vitamin D in addition to the nutritionally 
recommended amounts of 600 to 800 IU daily cannot 
currently be recommended for the prevention of 
cardiovascular events [22]. 
In consideration and critical review of four 
recent meta-analysis on vitamin D and fracture 
prevention, vitamin D supplementation with or without 
calcium is supported among adults aged 65 and over 
who are at risk for vitamin D deficiency and fractures, 
if administered daily or weekly equivalent monthly 
doses of 800 to 1000 IU and with good adherence. 
Vitamin D supplementation may not be effective in 
primary prevention among adults 50 years of age or 
older without vitamin D deficiency and osteoporosis. 
Monthly doses greater than 100,000 IU need further 
evaluation regarding efficacy and safety [23]. 
Another study of systematic review and meta-
analysis examined the effect of vitamin D 
supplementation on the serum lipid profile. The 
average vitamin D supplement per day was 2,795 IU. 
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Twenty-one trials were conducted in participants with 
diabetes, 13 studies were conducted in apparently 
healthy patients, and three trials were conducted in 
those who were obese or overweight. In 24 (68.6%) 
trials for which vitamin D deficiency (20 ng/mL) was 
reported at baseline, participants were sufficient 
vitamin D at the end of the trial. In 4 (11.4%) studies, 
no improvement was seen in serum vitamin D after the 
study. In 7 (20%) clinical trials, participants had 
sufficient vitamin D (> 20 ng/mL) both at baseline and 
at the end of the study. In 6 trials, both at baseline 
and at the end of the test serum vitamin D or serum 
vitamin D at the end of the test were not reported. A 
total of 41 randomized controlled trials comprising 
3434 participants (n = 1699 in the vitamin D 
supplementation arm and n = 1735 in the placebo 
arm) were identified and included in the meta-analysis. 
Approximately 63.4% of study participants were 
women, with 14 studies conducted entirely among 
women. Approximately 24% of the studies had a 
follow-up duration> 6 months, while the remaining 
76% had a follow-up duration <6 months. The 
improvements in total cholesterol and triglycerides 
were more pronounced in participants with baseline 
vitamin D deficiency. Vitamin D supplementation 
appears to have a beneficial effect in reducing serum 
levels of total cholesterol, LDL cholesterol, and 
triglycerides, but not HDL cholesterol levels. Vitamin D 
supplementation may be useful in patients with 
hypercholesterolemia with vitamin D insufficiency at 
high risk for cardiovascular disease [24]. 
Also, studies have suggested that vitamin D 
supplementation may increase serum fibroblast growth 
factor 23 (FGF23) among patients with vitamin D 
deficiency. Thus, a systematic review and meta-
analysis were performed to summarize all available 
data. Nine studies were eligible for meta-analysis. 
Seven studies measured serum intact FGF23 and two 
studies measured serum C-terminal FGF23. Meta-
analysis found that intact serum FGF23 increased 
significantly after oral vitamin D3 supplementation in 
participants with vitamin D deficiency. Serum C-
terminal FGF23 also increased after vitamin D3 
supplementation in participants with vitamin D 
deficiency [25]. 
Recent studies have shown that vitamin D 
supplementation decreases oxidative stress (OS) 
parameters. This systematic review and meta-analysis 
aimed to investigate the effect of vitamin D 
supplementation on the parameters of OS. In thirteen 
clinical trials, vitamin D supplementation increased 
serum levels of total antioxidant capacity (TAC) and 
glutathione. In addition, the concentration of 
malondialdehyde decreased significantly after vitamin 
D supplementation compared to placebo. There was 
no difference between the experimental and placebo 
groups in the subset of studies that administered 
vitamin D at less than 100,000 IU per month. 
However, a significant increase in TAC levels was 
found in the subset of studies that administered 
vitamin D between 100,000 to 200,000 IU and those 
that administered vitamin D between more than 
200,000 IU monthly [26]. 
Previous meta-analysis of RCTs on vitamin D 
supplementation and total incidence of cancer and 
mortality found inconsistent results, and most included 
studies that generally administered low doses of 
vitamin D (≤1100 IU/day). Thus, a recent meta-
analysis on RCT looked at higher doses of vitamin D 
supplements. For the total cancer incidence, 10 studies 
were included (6537 cases; 3-10 years of follow-up; 
54-135 nmol / L of levels reached circulating 25 (OH) 
vitamin D [25 (OH) D] in the intervention group). The 
summary RR was 0.98 (95% CI, 0.93-1.03; p = 0.42; 
I2 = 0%). The results remained null in the tested 
subgroups, including even when 25 (OH) D levels 
exceeding 100 nmol / L were reached (RR = 0.95; 
95% CI, 0.83-1.09; p = 0.48; I2 = 26%). For total 
cancer mortality, five trials were included (1591 
deaths; 3-10 years of follow-up; 54-135 nmol / L of 
levels reached 25 (OH) D circulating in the intervention 
group). Therefore, vitamin D supplementation 
significantly reduced total cancer mortality but did not 
reduce the total cancer incidence [27]. 
 
Vitamin D and COVID-19 
 In the COVID-19 scenario, a study analyzed 
the main functions of vitamin D in reducing the risk of 
respiratory tract infections. In this sense, the main 
mechanisms include the induction of cathelicidins and 
defensins that can reduce the rates of viral replication 
and reduce the concentrations of pro-inflammatory 
cytokines that produce inflammation that impairs the 
lining of the lungs, leading to pneumonia, in addition 
to increasing the concentrations of anti-inflammatory 
cytokines. Therefore, this study gathered literary 
information that vitamin D deficiency can contribute to 
acute respiratory distress syndrome, lethality rates 
with increasing age, and chronic disease comorbidity 
[28]. Thus, it is recommended to use 10,000 IU/day of 
vitamin D3 for a few weeks, followed by 5,000 IU/day, 
to increase and maintain 25 (OH) D concentrations 
between 40-60 ng/mL (100- 150 nmol/L) [28]. 
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Also, a recent literature review study revealed 
that because older adults are more likely to be 
diagnosed with Parkinson's disease (PD), advanced 
age is the biggest risk factor. In addition to its 
modulating effects on the immune system, it has been 
suggested that vitamin D supplementation plays a role 
in slowing the progression of PD and improving the 
quality of life. Therefore, daily supplementation of 
2000-5000 IU/day of vitamin D3 in elderly people with 
PD has the potential to slow the progression of PD, in 
addition to offering additional protection against 
COVID-19 [29]. 
Also, average vitamin D levels for 20 European 
countries and the morbidity and mortality caused by 
COVID-19 were acquired. There is a negative 
correlation between the average levels of vitamin D 
(average 56 mmol/L ± 10.61) in each country and the 
number of cases COVID-19/1 M (average 295.95 and 
mortality). Vitamin D levels are severely low in the 
aging population, especially in Spain, Italy and 
Switzerland, this is also the most vulnerable group of 
the population to COVID-19. It should be advisable to 
conduct dedicated studies on vitamin D levels of 
COVID-19 with varying degrees of disease severity 
[30]. 
To assess the general effect of vitamin D 
supplementation on the risk of acute respiratory tract 
infection and to identify the factors that modify this 
effect, a systematic review study and a meta-analysis 
of the individual data of the participants was carried 
out randomized clinical trials and  was obtained for 
10,933 (96.6%) participants. Vitamin D 
supplementation reduced the risk of acute respiratory 
tract infection among all participants. In subgroup 
analysis, protective effects were observed in those who 
received vitamin D daily or weekly without additional 
bolus doses, but not in those who received one or 
more bolus doses. Among those who received vitamin 
D daily or weekly, the protective effects were stronger 
in those with baseline levels of 25-hydroxyvitamin D 
<25 nmol/L than in those with baseline levels of 25-
hydroxyvitamin D ≥25 nmol/L. Therefore, vitamin D 
supplementation is safe and protected against acute 
respiratory tract infection in general. Patients with 
vitamin D deficiency and who did not receive bolus 
doses had the greatest benefit [31]. 
           
Limitations and BIAS 
The accuracy of vitamin D dosages varies 
widely between laboratories and between different 
assays, reaching up to 17 ng/mL. There are still 
differences in the extraction of vitamin D from its 
binding protein, a cross measurement of 25(OH)D2, 
25(OH)D3 and other metabolites in addition to the lack 
of standardization and, for this reason, quality control 
tools such as DEQAS (International Vitamin D External 
Quality Assessment Scheme) in an attempt to reduce 
these variations in data analysis. 
The most used methods today are competitive 
assays based on specific antibodies and non-
radioactive markers. The aim is to improve 
comparability between the results obtained with 
different methodologies. Whichever methods are 
employed, a precise definition of the normal range is 
essential. It is also noteworthy that the intra-individual 
variability can be from 12.1 to 40.3%. Clinical 
conditions that interfere with serum 25(OH)D levels 
are highly dependent on environmental and lifestyle 
factors, particularly exposure to UVB rays. 
 
Conclusion 
Dietary sources of vitamin D are scarce, and 
humans depend mainly on skin synthesis, making 
hypovitaminosis prevalent in most countries. 
Laboratory evaluation should be performed by 
measuring 25(OH)D, and the main groups of 
individuals at risk for vitamin D deficiency are the 
elderly, patients with osteoporosis, history of falls and 
fractures, obese, pregnant women and infants, 
patients taking medications that interfere with vitamin 
D metabolism (such as glucocorticoids, 
anticonvulsants, antifungals), patients with 
malabsorption syndromes, primary 
hyperparathyroidism, kidney or liver failure, 
granulomatous diseases, and lymphomas. 
For patients with osteoporosis and increased 
risk of fractures, recommended that concentrations of 
25(OH)D remain above 30 ng/mL for full benefits on 
the prevention of secondary hyperparathyroidism, 
decreased risk of falls, and for better impact on the 
health. For this maintenance, the doses need be 
between 1,000 and 2,000 IU. Special considerations 
must have taken to pregnant women and infants, in 
patients with chronic renal failure, obese patients, and 
those undergoing bariatric surgery. 
There are strong interests in vitamin D 
supplementation in an attempt to reduce various 
outcomes such as mortality, cardiovascular 
complications, diabetes, cancer, autoimmune diseases, 
cognitive function, among others. Thus, the several 
clinical studies and current meta-analysis have shown 
significant results with vitamin D supplementation in 
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these pathologies, with doses above 30 ng/mL, 
reaching up to 70 ng/mL and maintaining serum 
dosage at 50 ng/mL. 
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